Owlstone Medical, a global leader in Breath Biopsy for early disease detection and precision medicine, has announced a funding to the tune of $6.5 million.
Owlstone Medical's exegenous volatile organic compound (EVOC) breath test can reveal signs of liver cirrhosis and portal hypertension, a study has found.